- Home
- NAK vs COLL Comparison
NAK vs COLL Comparison
Compare NAK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAK | COLL |
|---|---|---|
| Founded | 1983 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2002 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NAK | COLL |
|---|---|---|
| Price | $1.59 | $35.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.50 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 4.7M | 337.9K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $88.95 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $0.77 | $29.70 |
| 52 Week High | $2.98 | $50.79 |
Technical Indicators
Market Signals| Indicator | NAK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.95 |
| Support Level | N/A | $33.93 |
| Resistance Level | N/A | $35.76 |
| Average True Range (ATR) | 0.00 | 1.24 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 37.03 |
Price Performance
Historical ComparisonAbout NAK Northern Dynasty Minerals Ltd.
Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.